H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the results of ...

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Kyverna reported $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which the Company ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Discover six of the top psychedelic companies developing novel drugs to expand the treatment scope for mental health ...

Oric Pharmaceuticals logged a wider loss in its latest quarter and said it plans to reduce investment in its discovery research group, resulting in a 20% workforce reduction.

Among Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis, treatment with the combination of pelabresib and ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...